Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels

International Journal of Gynecological Cancer

Volumn 20, Issue 6, 2010, Pages 936-944

  Bhosale, Priya ^a   Peungjesada, Silanath ^b   Wei, Wei ^a   Levenback, Charles F ^a   Schmeler, Kathleen ^a   Rohren, Eric ^a   MacApinlac, Homer A ^a   Iyer, Revathy B ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Accuracy; CA 125; CECT; FDG PET CT; Ovarian cancer; Recurrence

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOPSY; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CLEAR CELL CARCINOMA; CLINICAL EVALUATION; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MCNEMAR TEST; MEDICAL RECORD REVIEW; MIXED MULLERIAN TUMOR; MUCINOUS CARCINOMA; OVARY CANCER; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGIST; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; DIAGNOSTIC USE; EVALUATION STUDY; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; RADIOGRAPHY; REFERENCE VALUE; SCINTISCANNING; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 77956794299     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181e82a7f     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA CancerJ Clin. 2009;4:225-249.
2. Berek JS, Trope C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol. 1999;10:3-7.
3. Gadducci A, Cosio S, Zola P, et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2007;17:21-31.
4. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996; 7:361-364.
5. Gadducci A, Conte P, Cianci C, et al. Treatment options in patients with recurrent ovarian cancer. Anticancer Res. 2001;21: 3557-3564.
6. Sharma A, Bernacki RJ. Ovarian cancer patients with high CA-125 but no symptoms - should antiangiogenic treatments be considered? Oncol Res. 1997;9:53-54.
7. Fleming LW. Playing the waiting game... the asymptomatic patient with recurrent ovarian cancer detected only by rising Ca125 levels. Scot Med J. 2001;46:81-83.
8. Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007;8:813-821.
9. Rustin GJ. Should clinicians give second line chemotherapy after detecting elevated CA-125 levels? Chicago: ASCO. 2009.
10. Pannu HK, Cohade C, Bristow RE, et al. PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Abdom Imaging. 2004;29:398-403.
11. Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol. 2003;90:519-528.
12. Chung HH, Kang WJ, Kim JW, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging. 2007;34:480-486.
13. Pannu HK, Bristow RE, Cohade C, et al. PET-CT in recurrent ovarian cancer: initial observations. Radiographics. 2004;24: 209-223.
14. Thrall MM, DeLoia JA, Gallion H, et al. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol. 2007;105:17-22.
15. Grabiec M, Walentowicz M, Nowicki P. [The value of FDG PET/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma]. Ginekologia Polska. 2006;77:746-752.
16. Risum S, Hogdall C, Markova E, et al. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer. 2009;19:600-604.
17. Bristow RE, Giuntoli RL 2nd, Pannu HK, et al. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol. 2005;99: 294-300.
18. Rubin SC, Randall TC, Armstrong KA, et al. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 1999;93: 21-24.
19. Cotte E, Glehen O, Mohamed F, et al. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 2007;31:1813-1820.
20. Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76:2004-2010.
21. Hogberg T, Kagedal B. Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125. Gynecol Oncol. 1992;46:191-198.
22. Crombach G, Zippel HH, Wurz H. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors]. Geburtshilfe und Frauenheilkunde. 1985;45:205-212.
23. Gadducci A, Landoni F, Maggino T, et al. Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. Int J Gynecol Cancer. 1997;7:78-83.
24. Niloff JM, Bast RC Jr, Schaetzl EM, et al. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol. 1985;151:981-986.
25. Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23:9338-9343.
26. Ferrozzi F, Bova D, De Chiara F, et al. Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history. Clin Imaging. 1998;22:364-370.
27. Kubik-Huch RA, Dorffler W, von Schulthess GK, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol. 2000;10:761-767.
28. Lenhard MS, Burges A, Johnson TR, et al. PET-CT in recurrent ovarian cancer: impact on treatment planning. Anticancer Res. 2008;28:2303-2308.
29. Coakley FV, Choi PH, Gougoutas CA, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology. 2002;223:495-499.
30. Kainz C, Prayer L, Gitsch G, et al. The diagnostic value of magnetic resonance imaging for the detection of tumor recurrence in patients with carcinoma of the ovaries. J Am Coll Surg. 1994;178:239-244.
31. Garcia Velloso MJ, Boan Garcia JF, Villar Luque LM, et al. [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125]. Rev Esp Med Nucl. 2003;22:217-223.
32. Sebastian S, Lee SI, Horowitz NS, et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging. 2008;33: 112-118.
33. Fulham MJ, Carter J, Baldey A, et al. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol. 2009;112:462-468.
34. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155-2161.
35. Soussan M, Wartski M, Cherel P, et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol. 2008;108:160-165.
36. Fotiou S, Aliki T, Petros Z, et al. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer. Gynecol Oncol. 2009;114:178-182.
37. Yuan CC, Liu RS, Wang PH, et al. Whole-body PET with (fluorine-18)-2- deoxyglucose for detecting recurrent ovarian carcinoma. Initial report. J Reprod Med. 1999;44: 775-778.
38. Martinez-Roman S, Ramirez PT, Oh J, et al. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol. 2005;96:888-891.
39. Bristow RE, Simpkins F, Pannu HK, et al. Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer. Gynecol Oncol. 2002;85:196-200.
40. Sheng XG, Zhang XL, Fu Z, et al. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2007;42:460-463.
41. Zimny M, Siggelkow W, Schroder W, et al. 2-[Fluorine-18]-fluoro-2-deoxy- d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol. 2001;83:310-315. (Pubitemid 33033072)
42. Menzel C, Dobert N, Hamscho N, et al. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol. 2004;180: 497-501.
43. Steinert HC, Huch Boni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D- glucose. Radiology. 1995;195:705-709.
44. Makhija S, Howden N, Edwards R, et al. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol. 2002;85:53-58.
45. Berger KL, Nicholson SA, Dehdashti F, et al. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol. 2000;174:1005-1008.
46. Mansueto M, Grimaldi A, Mangili G, et al. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis. Eur J Cancer Care. 2009;18:612-619.